Content is not available

EQRx

Cambridge, MA
United States
https://www.eqrx.com/thestory

Booth: 5096a

Develop innovative cancer therapies at RADICALLY lower prices. It’s not simply our mission, it’s an invite to everyone in our industry to join us in making today’s innovative treatment options radically more accessible around the globe. Because a treatment doesn’t work for those that cannot afford them. EQRx is #RemakingMedicine, starting with two potential treatment options in lung cancer.

Brands: https://events.jspargo.com/ASCO21/CUSTOM/EQRx_BannerImage%202.jpg

Show Specials

Promising Results: Phase 3 Trial, Non-Small Cell Lung Cancer w/ EGFR (Jun 03, 2021)

<iframe width="560" height="315" src="https://www.youtube.com/embed/iKTRV0bZNeo" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>

Press Releases

4. Aumolertinib NSCLC Phase 3 Data (May 19, 2021)

https://www.eqrx.com/press-release/aumolertinib-significantly-prolongs-progression-free-survival-with-fewer-side-effects-in-the-first-line-treatment-of-advanced-egfr-mutated-non-small-cell-lung-cancer/

5. Sugemalimab NSCLC Phase 3 Results (Jun 03, 2021)

https://www.eqrx.com/press-release/primary-endpoint-met-in-phase-3-study-of-the-anti-pd-l1-antibody-sugemalimab-in-stage-iii-non-small-cell-lung-cancer/

1. Intro: Making Medicines Affordable (Jun 04, 2021)

https://www.eqrx.com/thestory/#thepriceproblem

2. An Unmet Clinical Need: Financial Toxicity (Jun 04, 2021)

https://www.eqrx.com/thestory/#loweringcosts

3. Lung Cancer Innovation Accelerated (Jun 04, 2021)

https://www.eqrx.com/thestory/#innovativemedicines

Products

AUMOLERTINIB’S IMPLICATIONS FOR LUNG CANCER

EQRx launched with a societal contract: high-quality, innovative new medicines—but at a fraction of the traditional cost. The compelling Phase 3 clinical results of aumolertinib and sugemalimab are a perfect example of this mission. We are committing to price these at a fraction of the cost typical for this level of innovation with an intent to improve global access. “If approved, aumolertinib could provide oncologists an option that not only reduces the traditional definition of toxicity—but one that also reduces the financial toxicity that unfairly burdens so many patients.” –EQRx’s Physician-In-Chief, Dr. Vince Miller... More Info Less Info

BUILDLING A NEW MODEL ACROSS THE INDUSTRY

Though our mission is simple, we are not naïve to the work it will take. EQRx is comprised of veterans from across every section of the healthcare industry who have come together to reimagine a new model of pharma. As an industry, we know the current system isn’t sustainable—and until we can confront the rising costs of healthcare, we can’t really create global health equity. Watch our insightful video series to learn how we are making this possible and join us in advocating for pricing to be a new frontier of healthcare innovation.... More Info Less Info

EQRx

Show Specials

Press Releases

Products

Categories

Contact this Exhibitor